# TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.

> **NCT00744809** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 120 (actual)

## Conditions studied

- Human Volunteers

## Interventions

- **DRUG:** TMC278; Moxifloxacin; Efavirenz

## Key facts

- **NCT ID:** NCT00744809
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2011-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744809, "TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00744809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*